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OBJECTIVE: Involvement of the left ventricular anterior wall in ST-elevation myocardial infarction has a worse
prognosis compared with other regions. In non-ST-elevation myocardial infarction, noninvasive methods of locating
the ischemic myocardial territory have been limited. The objective of this report is therefore to determine what
factors are predictive of the anterior location of the ischemic myocardial territory.
METHODS: This study included 170 patients with non-ST-elevation myocardial infarction. Clinical, echocardio-
graphic, and laboratory characteristics, including B-type natriuretic peptide measured within 24 hours of
hospitalization, and coronary angiographic features were analyzed.
RESULTS: The mean age was 64.5 ¡ 12.3 years, and 112 of the patients were male (66%). The median follow-up was
23 months. The territory involved, as determined from the angiogram, was divided into anterior [n=80 (47%)]
regions and inferior and lateral [n=90 (53%)] regions. Multivariate analysis showed that B-type natriuretic peptide
was the only independent predictor of an anterior wall infarct [OR=3.70 (95% CI: 1.61 – 8.53); P=0.002] in non-ST-
elevation myocardial infarction patients. Multivariate analysis also showed that B-type natriuretic peptide was an
independent predictor of in-hospital cardiac events during index admission [OR=5.05 (95% CI: 1.49 – 17.12);
P=0.009] and of cardiac events occurring during follow-up [HR=1.79 (95% CI: 1.05 – 3.04); P=0.032].
CONCLUSIONS: B-type natriuretic peptide was the only factor independently associated with anterior wall
involvement in non-ST-elevation myocardial infarction, and the peptide levels upon admission predicted in-hospital
and subsequent cardiac events.
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INTRODUCTION
Previous studies
1,2 have shown that involvement of the
left ventricular (LV) anterior wall in ST-elevation myocar-
dial infarction (STEMI) has a worse prognosis compared
with involvement of other regions. STEMI of the anterior
wall is associated with a larger infarction area, as
determined by the enzyme peak and lower left ventricular
ejection fraction (LVEF), in comparison with other walls.
3
Also, the electrocardiogram (ECG) in STEMI is usually
sufficient to diagnose which wall is affected.
4
The importance of the involvement of the anterior wall in
patients with non-ST-segment elevation myocardial infarc-
tion (NSTEMI) has not been widely studied. In NSTEMI, the
identification of involvement of the anterior wall on
admission is not as obvious as in STEMI. Because anterior
wall infarction may be associated with a poor prognosis,
several studies
5-8 have been conducted to identify the
ischemic LV wall in NSTEMI. These studies have used
ECG to identify which wall was affected. However, ECG has
limited ability to perform this function in NSTEMI because
approximately 50% of patients have a normal or incon-
clusive pattern.
9 Other methods, such as stress echocardio-
graphy
10 and myocardial perfusion scintigraphy,
11 can
locate the infarction site in NSTEMI patients, but both
methods demand more complex health services and higher
costs. However, in a recent report by Sadanandan et al.
12 of
patients with unstable angina and NSTEMI, coronary
angiography showed an association between BNP levels
and involvement of the anterior descending coronary artery.
The identification of myocardial ischemia involving the
anterior wall in NSTEMI has potential utility in terms of
patient management and prognosis.
7 The objective of this
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437study was therefore to determine whether BNP levels can
facilitate the identification of anterior wall myocardial
ischemia in NSTEMI.
MATERIALS AND METHODS
Study Patients
This prospective study was composed of 170 consecutive
patients with NSTEMI who were seen between January 2005
and April 2006 and who were followed during and after
hospitalization until September 2007. The median length of
their hospital stay was 3 days (range: 1 to 125), and the
median follow-up was 23 months (range: 0.04 to 32).
Patients diagnosed with NSTEMI were selected according
to the international consensus definition.
13 The Ethics
Committee of the Heart Institute (InCor) approved this
study, and written informed consent was obtained from all
participants.
Laboratory Analyses
Routine blood samples were collected at admission with-
out regard to fasting status, and the troponin I, creatine
kinase isozyme by mass assay (CK-MB), andBNP levels were
measured. For the BNP determination, a specific kit for the
ADVIA Centaur analyzer (Bayer Health Care Diagnostics,
Tarrytown, NY) was used, which had a detection limit of
2 pg/mL and range from 2 to 5000 pg/mL. The intra- and
interassaycoefficientsofvariationrangedfrom 2.1to4.7% for
concentrations between 29 and 1700 pg/mL . For this study,a
level of $100 pg/mL was considered abnormal based on the
manufacturer’s recommended cut-off value.
14,15
Electrocardiography
ECGs were performed upon hospital admission and were
repeated soon after medication was started. ECGs were
analyzed blind to the results of coronary angiography. Each
tracing was evaluated by two cardiologists for the presence
or absence of acute ischemic changes based on the presence
or absence of (1) ST-segment depression $ 0.5 mm and (2) T
wave changes. Patients with acute ischemic changes were
categorized according to the location of the acute ischemic
region into groups with anterior (V1, V2, V3, V4), inferior
(DII, DIII, aVF), or lateral wall (V5, V6, DI, aVL) involvement.
Echocardiography
Images were acquired using a transthoracic approach
with M-mode, 2-dimensional, spectral Doppler (pulsed and
continued) and color flow mapping. The LVEF was
calculated using Simpson’s method.
Angiographic Analysis
The angiography results were evaluated by physicians
blinded to the ECG and enzyme values. Using angiography,
the wall involved in the acute ischemia was determined by
identifying the artery affected by a ruptured atherosclerotic
plaque, a thrombus, or both. Criteria for identification were
an eccentric lesion, cut or overlaying borders, a blurred
lesion, globular intraluminal masses, contrast retention, and
slow coronary flow.
16
Clinical Events
The following events were recorded and used in the
analyses:
(1) in-hospital events during index admission including
composite endpoint by the first occurrence of (a)
mortality in-hospital during index admission or (b)
cardiovascular events including congestive heart fail-
ure, cardiogenic shock, or ischemic events; and
(2) any events during follow-up including composite end-
point by the first occurrence of (a) in-hospital event
during index admission, (b) mortality during follow-up,
or (c) rehospitalization for any cause.
Statistical Analysis
Normally distributed quantitative variables are expressed
as means and standard deviations. Nonparametric variables
are expressed as median, minimum, and maximum values.
Differences in the distribution of selected characteristics
between patient groups were examined using the chi-square
test and Fisher’s exact test for categorical variables. The
analysis was performed using Student’s t-test for normally
distributed continuous variables and the Mann-Whitney
and Kruskal-Wallis tests for nonparametric variables.
Variables associated with wall location and events in
univariate analysis (P , 0.10) were included in the multi-
variate analyses. Continuous variables were used as
dichotomous variables to facilitate clinical interpretation
and standardize the multivariate analysis. The receiver
operating characteristic (ROC) curve was used to determine
the area under the curve (AUC) or the c statistic; the cut-off
point for BNP and other continuous variables with the best
predictive value was used for wall location and cardiac
events. A multiple logistic regression model was used for
the selection of variables predictive of involvement of the
anterior wall and for the occurrence of in-hospital events
during index admission. Cox multivariate regression was
used for the selection of independent prognostic factors
of mortality and any follow-up events. Two-sided P
values , 0.05 were considered statistically significant. All
statistical analyses were performed using the Statistical
Package for Social Sciences (SPSS) software version 11.0 for
Windows.
RESULTS
Table 1 presents clinical and demographic characteristics
of the patients. The median BNP level at baseline was
214.5 pg/mL (range: 7 to 2291); moreover, 66% of patients
had BNP $ 100 pg/mL (116 patients). The median peak
troponin I level was 6.9 ng/mL (range: 1 to 150), and the
median peak CK-MB level was 19 ng/mL (range: 2 to 500).
The echocardiogram LVEF was normal ($ 55%) in 55
patients (32%), and the median LVEF was 47%. No
statistically significant differences were observed between
LVEF values regarding involvement of the anterior and
lateral/inferior walls.
ECG review was used to identify the wall involved, but
the location of the ischemic territory in almost half (71
patients, 42%) of the patients could not be categorized. ECG
successfully showed anterior wall involvement in 43
patients (25%), and inferior or lateral wall involvement in
56 patients (33%).
The most frequent treatment was PTCA, which was
performed in 85 patients (50%), followed by medical
treatment in 68 patients (40%), and CABG in 17 patients
(10%).
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438Anterior vs. Inferior and Lateral Wall Location of
Acute Myocardial Ischemia
Univariate analysis identified the significant predictive
factors for anterior wall location to be a BNP level . 210 pg/
mL [RR = 1.78 (95% CI: 1.28-2.47); P,0.001] and anterior
wall involvement on ECG [RR = 3.02 (95% CI: 2.02 – 8.00);
P,0.001]. A multivariate logistic regression analysis, how-
ever, revealed that a BNP level . 210 pg/mL remained the
only independent predictor of the anterior wall as the
location of acute myocardial ischemia [OR = 3.70 (95% CI:
1.61 – 8.53); P=0.002].
Any events during follow-up
The analysis using Cox multivariate regression of any
events during follow-up showed that BUN levels . 39 mg/
dL [HR= 1.82 (95% CI: 1.13 – 2.94); P=0.014], baseline BNP
values . 156 pg/mL [HR = 1.79 (95% CI: 1.05 – 3.04),
P=0.032], and family history for CAD [HR = 0.61 (95% CI:
0.38 – 0.99); P=0.045] were independent predictors among
those evaluated.
The Kaplan-Meier analysis showed a trend toward a
greater risk of any event during follow-up (P for trend =
0.064) when comparing anterior wall involvement with
inferior or lateral wall involvement (Table 2, Figure 1).
Mortality
Cox multivariate analysis showed that previous heart
failure [HR = 3.71 (95% CI: 1.44 – 9.58); P=0.007] and
history of chest pain [HR = 0.28 (95% CI: 0.10-0.76);
P=0.012] were other independent predictors of mortality
among those evaluated.
DISCUSSION
Our study shows that the BNP level was the only variable
able to locate ischemic myocardium in the LV anterior wall
in patients with NSTEMI, independent of multiple other
characteristics including heart disease risk factors and
history of previous cardiovascular disease. Previous stu-
dies
5,6,17 have evaluated the location of the LV anterior wall
in NSTEMI in relation to the prognosis, with most using
ECG to identify the affected wall. For example, using
electrocardiographic ST-segment and T-wave changes to
categorize the patients, Kao et al.
5 studied 135 patients with
NSTEMI and observed a higher rate of reinfarction and
death in patients with involvement of the anterior wall in
Table 1 - Baseline characteristics of the overall patient population by ischemic wall as defined by angiography.
Variable
All patients
n=170 (%)
Anterior
n=80 (%)
Inferior / lateral
n=90 (%) P*
Demographic characteristics
Age, years 64.5¡12.3 62.9¡11.4 63.9¡11.3 0.571
Male sex, n (%) 112 (66) 49 (61) 63 (70) 0.230
Clinical characteristics
Onset of symptoms, hours 7.4 (0.1 – 170) 7.4 (0.3-145) 7 (0.1-170) 0.921
History of chest pain, n (%) 157 (92) 75 (94) 82 (91) 0.518
History of dyspnea, n (%) 43 (25) 21 (26) 22 (24) 0.789
Hypertension, n (%) 146 (86) 71 (89) 75 (83) 0.311
Hypercholesterolemia, n (%) 108 (63) 48 (60) 60 (67) 0.367
Diabetes mellitus, n (%) 66 (39) 30 (38) 36 (40) 0.738
Family history of CAD, n (%) 65 (38) 30 (38) 35 (39) 0.955
Current smoking, n (%) 36 (21) 15 (19) 21 (23) 0.465
Previous PTCA, n (%) 45 (27) 21 (26) 24 (27) 0.951
Previous CABG, n (%) 37 (22) 14 (18) 23 (26) 0.204
Previous myocardial infarction, n (%) 79 (47) 34 (43) 45 (50) 0.328
Previous heart failure, n (%) 33 (19) 17 (21) 16 (18) 0.568
Laboratory tests
Baseline BNP, pg/mL 214.5 (7-2291) 247 (7-1843) 100 (12-1738) 0.002
Peak CK-MB mass, ng/mL 19 (2-500) 22 (2.4-500) 22.8 (2-455) 0.677
Peak troponin I, ng/mL 6.9 (1-150) 7.3 (1-150) 7.8 (1-150) 0.845
Electrocardiographic characteristics
Anterior wall location, n (%) 43 (25) 36 (45) 7 (8) ,0.001
Inferior or lateral wall location, n (%) 56 (33) 13 (16) 43 (48) ,0.001
Echocardiographic features
LVEF, % (range) 47 (10-77) 45 (12-77) 50 (10-74) 0.292
Angiographic characteristics, n (%)
1-vessel disease 39 (23) 23 (29) 16 (18) 0.089
2-vessel disease 44 (26) 22 (28) 22 (24) 0.650
3-vessel disease 87 (51) 35 (44) 52 (58) 0.068
CAD = coronary artery disease; PTCA = percutaneous transluminal coronary angioplasty; CABG = coronary artery bypass grafting; LVEF = left ventricular
ejection fraction; * P values for the comparison between the anterior wall and inferior/lateral wall.
Table 2 - Any events of the overall patient population by
ischemic wall as defined by angiography.
Events
Anterior
patients,
n=80 (%)
Inferior / lateral
patients,
n=90 (%)
Any in-hospital cardiovascular
event
27 (34) 16 (14)
Congestive heart failure 19 (24) 14 (13)
Cardiogenic shock 8 (10) 2 (1)
All causes of death 12 (15) 14 (15)
In-hospital 5 (6) 2 (2)
During follow-up 7 (9) 12 (14)
Rehospitalization 30 (38) 28 (31)
Acute coronary syndrome 18 (22) 15 (17)
Congestive heart failure 5 (7) 5 (6)
Non-cardiac events 7 (9) 8 (9)
CLINICS 2011;66(3):437-441 BNP and location of NSTEMI
Ramos RB et al.
439comparison with the inferior and lateral walls. In addition,
Schechtman et al.
17 analyzed data from 544 patients with
NSTEMI, excluding patients in Killip class IV. Using ECG to
categorize the infarct location, they identified 51% of
patients as having anterior wall ischemia and did not find
higher mortality in these patients compared with those who
had ischemia of the inferior or lateral walls. They did not
locate the wall affected in 20% of their patients.
Compared with these studies, the infarct location was not
categorized in a greater number of patients in the present
study. This may be due to our use of the new definition of
NSTEMI, which includes a smaller area of infarct or
ischemia that may have a smaller representation on ECG.
The presence of other factors, such as previous MI, cardiac
surgery, or left bundle-branch block, can also influence the
accuracy of ECG.
Similar to the present study, Haim et al.
6 used ECG to
categorize patients with the first NSTEMI in the anterior or
inferior and lateral walls and showed a higher rate of
cardiac events in patients with NSTEMI of the anterior wall
during a 1-year follow-up.
All three of the above studies showed a higher incidence
of heart failure in patients with NSTEMI of the anterior wall
compared with the other walls. In our study, we observed
previous heart failure in 21% of patients with involvement
of anterior wall and in 18% of those with inferior and lateral
wall ischemia.
In the present study, a broad comparative analysis was
performed to identify the variables with the greatest ability
to determine involvement of the LV anterior wall versus
inferior and lateral walls in NSTEMI patients, based on the
location defined by coronary artery angiography. Although
it is sometimes difficult to define the coronary artery
involved, the culprit coronary artery was successfully
identified for patients in this study. Patients with involve-
ment of the LV anterior wall on angiography had a higher
frequency of detection of anterior wall location by ECG
(P,0.001) and higher BNP levels (P=0.002) (Table 1). In the
final logistic regression multivariate analysis, the baseline
BNP value remained the only independent predictor of
involvement of the LV anterior wall [OR = 3.70 (95% CI:
1.61 – 8.53); P=0.002].
Serum BNP levels are associated with ventricular dys-
function in ACS. Additionally, several studies
12,18,19 have
shown an association between high BNP levels and acute
myocardial ischemia. Sadanandan et al.
12 reported that high
BNP levels in unstable angina and NSTEMI were associated
with tighter culprit vessel stenosis and lower flow in the
artery involved, and the culprit artery was most often the
anterior descending artery. Furthermore, Palazzuoli et al.
18
selected a group of patients with stable angina, unstable
angina, and NSTEMI and showed that elevated BNP levels,
even in the absence of heart failure, were related to 3- or 4-
vessel disease in comparison with 1- or 2-vessel disease.
Elevated BNP levels were also shown to be indicative of
involvement of the anterior descending artery.
The aforementioned studies
12,18 used univariate analysis
to show a correlation between higher BNP levels and
involvement of the anterior descending coronary artery.
Conversely, the present study considered a broad set of
variables to identify those with an independent ability to
locate the involvement of the anterior wall. The independent
and apparently exclusive ability of the BNP levels to predict
the location in the LV anterior wall in a population sample
including patients with a high frequency of previous heart
failure may be explained by its correlation with the ischemic
myocardial area at risk in this cohort.
Risk stratification scores in NSTEMI are valued by current
medical practices. The scores frequently used today are
the American College of Cardiology/American Heart
Association (ACC/AHA) prognostic classification
20 and
the TIMI (Thrombolysis in Myocardial Infarction) risk
score.
21 However, neither of these scores includes baseline
BNP values. In a recent study, Khan et al.
22 used multi-
variate analysis to show that, in STEMI, the N-terminal pro-
BNP (NT-proBNP) value measured within the first 24 hours
of admission was a better prognostic factor than the TIMI
risk score at predicting mortality. In addition, Bazzino et
al.
23 reported that in patients with non-ST-elevation ACS,
the NT-proBNP level adds substantial information to the
TIMI risk score and ACC/AHA classification.
In the present study, there was a trend of more in-hospital
events during index admission when the anterior wall was
involved in NSTEMI when compared with patients with
inferior and lateral wall ischemia. The Kaplan-Meier
analysis also showed a tendency for patients with
NSTEMI to have a higher frequency of any clinical event
during follow-up (Figure 1). In the SPRINT study, the
anterior wall infarction location was an independent
predictor of the occurrence of composite events (death and
rehospitalization for ACS) during a 1-year follow-up.
6 The
present results may have been affected by differences
between the populations and type of treatment performed
in the two groups; more specifically, there was a high
frequency of PTCA of the culprit artery (50%), CABG (10%),
and drug therapy (40%), which likely reduced the recurrent
event rate.
Study limitations
The small number of deaths limited the analysis and
interpretation of mortality for the population sample. The
cut-off points calculated for the continuous variables using
the ROC curve were valid for this cohort, but further studies
Figure 1 - Kaplan-Meier any event-free survival curve during
follow-up, in months, for patients with NSTEMI and according to
the involvement of anterior vs. inferior and lateral walls as
defined by angiography.
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practice.
CONCLUSION
BNP can independently predict the involvement of the
anterior wall in comparison with the inferior or lateral walls
in NSTEMI. This may explain one of the underlying
mechanisms accounting for the independent ability of the
baseline BNP levels to predict events during index admis-
sion hospitalization and long-term follow-up.
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